Hyper‐acetylation contributes to the sensitivity of chemo‐resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A

Therapeutic agents are urgently needed for treating metastatic castration‐refractory prostate cancer (mCRPC) that is unresponsive to androgen deprivation and chemotherapy. Our screening assays demonstrated that chemotherapy‐resistant prostate cancer (PCa) cells are more sensitive to HDAC inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qingqing, Liu, Xiaofei, Zhu, Shiqin, Hu, Xuelei, Niu, Huanmin, Zhang, Xiulei, Zhu, Deyu, Nesa, Effat Un, Tian, Keli, Yuan, Huiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824406/
https://www.ncbi.nlm.nih.gov/pubmed/29327812
http://dx.doi.org/10.1111/jcmm.13475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824406/
https://www.ncbi.nlm.nih.gov/pubmed/29327812
http://dx.doi.org/10.1111/jcmm.13475

Ejemplares similares